Longevity in Australia.

Runs its own lab, "Optilabs". Leadership UNVERIFIED by name, left unset rather than guessed.

AU$65M Series A led by Airtree (16 Jun 2026), with Plural, Left Lane, b2venture and Pat Cummins; ~AU$80M total raised; UK named as next market. Transparent pricing.

R2 correction: a SINGLE Sydney clinic, not multi-city. The multi-city executive-health footprint belongs to a separate, unrelated operator (Executive Health Solutions), do not merge.

Runs the "HELP" programme.

Australia's most comprehensive in-house concierge programme.

Concierge model. Distinct from Singapore's "The Longevity GP".

Clinical-stage biotech developing disease-modifying drugs for neurodegenerative disease. Lead candidate ATH434 is an oral small molecule designed to reduce excess iron accumulation in the brain and inhibit aggregation of alpha-synuclein, the protein implicated in Multiple System Atrophy and related synucleinopathies. It targets the underlying biology of age-related neurodegeneration rather than symptoms, which is the longevity-relevant part. ATH434 has completed a randomised placebo-controlled Phase 2 trial in MSA plus an open-label Phase 2 in advanced MSA, and the company is working toward a pivotal Phase 3. It is a single-asset, pre-revenue developer, so exposure is binary on that program.

Develops inhaled splice-switching oligonucleotide (RNA) drugs aimed at the RAGE receptor, the receptor for advanced glycation end-products. Lead candidate RB042 inhibits full-length RAGE while increasing the soluble decoy form esRAGE in the lung, with the goal of damping chronic airway inflammation. It is in a Phase 1 trial (NCT07285122) in healthy volunteers and healthy smokers, targeting COPD; the stated pipeline also covers alpha-1 antitrypsin deficiency, neutrophilic asthma and idiopathic pulmonary fibrosis. The longevity relevance is mechanistic rather than claimed by the company: RAGE-AGE signalling sits at the intersection of two recognised ageing hallmarks, chronic sterile inflammation and the accumulation of glycation end-products, and the company itself positions RB042 as a respiratory disease drug, not an ageing intervention. Note the company was spun out as RAGE Biotech, jointly founded with IP Group Australia, Monash University, Murdoch University, the University of Western Australia, and the Baker and Perron institutes, and now operates as Atisama Therapeutics.

Clinical-stage radiopharmaceutical company. Its SAR Technology platform pairs copper-64 (imaging) and copper-67 (therapy) with the same targeting molecule, so a single agent can both find and treat a tumour. Three candidates: SAR-bisPSMA (prostate cancer, lead), SAR-Bombesin (prostate and other PSMA-negative tumours) and SARTATE (neuroendocrine tumours). Relevance to the variis universe is late-life cancer detection and treatment: prostate and neuroendocrine cancers are strongly age-associated, and the company's clinical case rests on detecting recurrent disease at low PSA levels, i.e. earlier than standard-of-care imaging. Nothing in the pipeline targets ageing biology directly. Qualifies on limbs (a) and (b): ASX-listed and Australian-headquartered. Note it is pre-revenue and pre-approval; no product has regulatory approval.

Melanocortin photomedicine (tissue resilience).

Hearing implants (hearing loss is a modifiable dementia-risk factor).

Plasma immunoglobulins, gene therapy.

Clinical-stage biopharmaceutical company. Its lead candidate DMX-200 (repagermanium, a chemokine receptor CCR2 antagonist given on top of an angiotensin II receptor blocker) is in the Phase 3 ACTION3 trial for focal segmental glomerulosclerosis (FSGS), a rare glomerular disease that causes scarring of the kidney's filtering units and progressive loss of kidney function toward end-stage renal disease. The trial's primary endpoint is reduction in proteinuria, with eGFR decline as a longer-term measure. A second program, DMX-700, targets orphan respiratory and renal indications and is at an earlier stage. The longevity relevance is narrow and indirect: this is rare-disease nephrology, not a geroscience or ageing-biology program. It is relevant to healthspan only insofar as declining kidney filtration is one of the core organ-decline endpoints, and DMX-200 addresses a specific genetic and idiopathic kidney disease rather than age-related renal decline in the general population. No approved products and no revenue from product sales; the company is pre-approval and dependent on trial outcomes and regional licensing partners.

Telehealth group founded in Sydney in 2019, operating four direct-to-consumer clinical brands: Juniper (weight management built around GLP-1 receptor agonist prescribing plus coaching), Pilot (men's health, including weight, hair loss and sexual health), Software (dermatology and skincare) and Kin (contraception, fertility and pregnancy). Its longevity relevance is distribution rather than discovery: it does not develop drugs or run biology research, but is one of the larger channels in Australia through which GLP-1 metabolic therapy is prescribed, titrated and monitored remotely, with adherence support attached. Reported 2024 revenue of A$120.9m and an after-tax loss of A$15.2m. Qualifies under limb (b), Australia-headquartered, though since June 2026 it has been a wholly owned subsidiary of NYSE-listed Hims & Hers Health rather than an independent company.

Across eighteen months, the region's longevity capital has taken three distinct shapes: a Melbourne clinic's seed to Series A climb, a Singapore drug discovery company's Hong Kong listing, and a five year commitment to build a flagship clinic from scratch. Together they sketch what type of longevity business Singapore and Australia capital is actually prepared to back.